Infertility Survey Among Reproductive Age Women With Gynecological and Breast Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04678414 |
|
Recruitment Status :
Recruiting
First Posted : December 22, 2020
Last Update Posted : December 22, 2020
|
Sponsor:
M.D. Anderson Cancer Center
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This study develops infertility survey among reproductive age women with gynecological and breast cancer. This study aims to learn how women consider whether or not to try to have a baby after surviving cancer. The advice gathered from this survey may be shared with patients and survivors in the future, so that they have information to inform their decisions about cancer treatment and family planning.
| Condition or disease | Intervention/treatment |
|---|---|
| Anatomic Stage I Breast Cancer AJCC v8 Anatomic Stage IA Breast Cancer AJCC v8 Anatomic Stage IB Breast Cancer AJCC v8 Anatomic Stage II Breast Cancer AJCC v8 Anatomic Stage IIA Breast Cancer AJCC v8 Anatomic Stage IIB Breast Cancer AJCC v8 Anatomic Stage III Breast Cancer AJCC v8 Anatomic Stage IIIA Breast Cancer AJCC v8 Anatomic Stage IIIB Breast Cancer AJCC v8 Anatomic Stage IIIC Breast Cancer AJCC v8 Endometrial Carcinoma Female Reproductive System Disorder Prognostic Stage I Breast Cancer AJCC v8 Prognostic Stage IA Breast Cancer AJCC v8 Prognostic Stage IB Breast Cancer AJCC v8 Prognostic Stage II Breast Cancer AJCC v8 Prognostic Stage IIA Breast Cancer AJCC v8 Prognostic Stage IIB Breast Cancer AJCC v8 Prognostic Stage III Breast Cancer AJCC v8 Prognostic Stage IIIA Breast Cancer AJCC v8 Prognostic Stage IIIB Breast Cancer AJCC v8 Prognostic Stage IIIC Breast Cancer AJCC v8 Stage I Uterine Corpus Cancer AJCC v8 Stage IA Cervical Cancer AJCC v8 Stage IA Ovarian Cancer AJCC v8 Stage IA Uterine Corpus Cancer AJCC v8 Stage IA1 Cervical Cancer AJCC v8 Stage IA2 Cervical Cancer AJCC v8 Stage IB1 Cervical Cancer AJCC v8 Stage IC Ovarian Cancer AJCC v8 | Behavioral: Healthcare Activity Other: Survey Administration |
PRIMARY OBJECTIVES:
I. To tailor the National Fertility Barriers (NFB) Survey for women who have had gynecological and breast cancers.
II. To administer the tailored survey and evaluate if utilization of infertility clinics and treatments is associated with pregnancies leading to live births after gynecological or breast cancer.
SECONDARY OBJECTIVE:
I. To evaluate whether potential covariates are associated with utilization of infertility clinics and live births after gynecological and breast cancers (e.g. socio-demographic, clinical, psychological, lifestyle, and decision-making characteristics).
OUTLINE:
FOCUS GROUP: Patients attend an audiotaped focus group over 90 minutes to provide feedback for survey development.
SURVEY VALIDATION: Patients complete an online survey over 15-30 minutes at baseline and 2 days later.
TELEPHONE SURVEY: Patients complete a telephone survey.
| Study Type : | Observational |
| Estimated Enrollment : | 1410 participants |
| Observational Model: | Cohort |
| Time Perspective: | Cross-Sectional |
| Official Title: | Infertility Survey Among Reproductive Age Women With Gynecological and Breast Cancer |
| Actual Study Start Date : | April 1, 2019 |
| Estimated Primary Completion Date : | August 1, 2022 |
| Estimated Study Completion Date : | August 1, 2022 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Breast cancer
MedlinePlus related topics:
Infertility
| Group/Cohort | Intervention/treatment |
|---|---|
|
Observational (focus group, survey)
FOCUS GROUP: Patients attend an audiotaped focus group over 90 minutes to provide feedback for survey development. SURVEY VALIDATION: Patients complete an online survey over 15-30 minutes at baseline and 2 days later. TELEPHONE SURVEY: Patients complete a telephone survey. |
Behavioral: Healthcare Activity
Attend focus group
Other Names:
Other: Survey Administration Complete survey |
Primary Outcome Measures :
- Underlying constructs [ Time Frame: Up to 3 years ]Will be measured by the Oncofertility Barriers Scale. Will perform factor analysis using principal axis factoring with oblique rotation to simplify the construct interpretation.
- Known-group validity [ Time Frame: Up to 3 years ]Will use t-test to compare two groups. If the distributional assumptions are not met, will use the Mann Whitney test.
- Convergent validity [ Time Frame: Up to 3 years ]Will correlate Oncofertility Barriers Scale scores with Evaluation and Nurturing Relationship Issues, Communication and Happiness scores. Analysis of variance will be used to generate a generalizability coefficient for relevant factors, as distributions allow. As distributions allow, will also assess a priori hypotheses that divergence will be observed among groups of women with different ages, cancer types, time since completing cancer treatment, and priori fertility concerns, as well as access to and utilization of fertility care. All tests will be two-sided and use a significance level of 0.05.
- Live birth [ Time Frame: Up to 3 years ]Will compare cancer diagnosis, treatment characteristics and patient reported survey results by live birth (yes versus no) using a 2-sample t-test (or Wilcoxon depending on underlying distribution) and chi-squared test (or Fisher's exact test). Will also conduct logistic regression analysis regressing live birth on predictors of interest, and build a multivariable model based on univariate results including all terms significant at the 0.10 level then refining the model using backwards selection to include variables significant at the 0.05 level in the final model.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 45 Years (Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Women seen at the MD Anderson Oncofertility Clinic and Adolescent and Young Adult Program or women in the California Cancer Registry
Criteria
Inclusion Criteria:
- FOCUS GROUP: Women seen at the MD Anderson Oncofertility Clinic and Adolescent and Young Adult Program who are 18-45 years old at the time of cancer diagnosis
- SURVEY VALIDATION: Women seen at the MD Anderson Oncofertility Clinic and Adolescent and Young Adult Program who are 18-45 years old at the time of cancer diagnosis
- TELEPHONE SURVEY: Women in the California Cancer Registry
- TELEPHONE SURVEY: Are 18-45 years old
- TELEPHONE SURVEY: Were diagnosed with early-stage ovarian (IA and IC), endometrial (IA), cervical (IA1-IB1), or breast cancer (I-III)
- TELEPHONE SURVEY: Are 5-12 years post diagnosis between the years of 2007-2014
- TELEPHONE SURVEY: Underwent fertility-preservation treatments
Exclusion Criteria:
- FOCUS GROUP: Do not speak English or Spanish
- SURVEY VALIDATION: Do not read and understand English
- TELEPHONE SURVEY: Do not speak English or Spanish
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04678414
Contacts
| Contact: Jose A Rauh-Hain | 713-794-1759 | jarauh@mdanderson.org |
Locations
| United States, Texas | |
| M D Anderson Cancer Center | Recruiting |
| Houston, Texas, United States, 77030 | |
| Contact: Jose A. Rauh-Hain 713-794-1759 jarauh@mdanderson.org | |
| Principal Investigator: Jose A. Rauh-Hain | |
Sponsors and Collaborators
M.D. Anderson Cancer Center
Investigators
| Principal Investigator: | Jose A Rauh-Hain | M.D. Anderson Cancer Center |
Additional Information:
| Responsible Party: | M.D. Anderson Cancer Center |
| ClinicalTrials.gov Identifier: | NCT04678414 |
| Other Study ID Numbers: |
2018-0477 NCI-2020-08295 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) 2018-0477 ( Other Identifier: M D Anderson Cancer Center ) |
| First Posted: | December 22, 2020 Key Record Dates |
| Last Update Posted: | December 22, 2020 |
| Last Verified: | December 2020 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Breast Neoplasms Ovarian Neoplasms Carcinoma, Ovarian Epithelial Uterine Cervical Neoplasms Endometrial Neoplasms Infertility Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Endocrine Gland Neoplasms Ovarian Diseases |
Adnexal Diseases Genital Neoplasms, Female Urogenital Neoplasms Endocrine System Diseases Gonadal Disorders Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Uterine Neoplasms Uterine Cervical Diseases Uterine Diseases |